Recent News
Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein antibody (ACPA)-negative people with clinically suspect arthralgia.Read Article
Antidepressants for Pain are Weakly Effective
EurekAlert!
University of Sydney research has found people over 65 are being prescribed antidepressants as pain treatment based on international guidelines that use limited evidence. The study found that in the last 40 years there have been only 15 trials globally focusing on the benefit of antidepressants for pain in older people. This study fills a much-needed gap in research by bringing together the information from these trials to look at the
Read Article
Study extended - People with #lupus #SLE: We'd love to hear about your experiences. Either use the link below or scan the QR code with another device. https://t.co/gbmn8PWbwd https://t.co/MHLbDdCGbf
Links:
Julia Simard, ScD @RheumEpi ( View Tweet)
Full read review of Neonatal lupus syndrome - caused by pathogenic maternal autoAbs (SSA, SSB) in fetal circulation. Mild Sxs in 25%, severe Sxs are rare; Heart block in up to 2% of neonates born to mothers with positive antibodies. https://t.co/CmhnH4DOXX https://t.co/fOzOhaNjkS
Dr. John Cush @RheumNow ( View Tweet)
BSR Guidelines for Systemic Sclerosis Management
The BSR has updated its 2015 guidelines for the management of patients with SSc based on published evidence, systematic literature review and expert opinion.
https://t.co/i4mSYnRYwO https://t.co/Z9pxxe2jsc
Dr. John Cush @RheumNow ( View Tweet)
Increased Cardiovascular Events in Lupus
A New York surveillance registry (Manhattan Lupus Surveillance Program) estimates higher rates of CVE among SLE patients, especially amongst younger males, Hispanic/Latinos and non-Hispanic Black patients.
https://t.co/aUZreOSbaD https://t.co/SAB5bl3Wdo
Dr. John Cush @RheumNow ( View Tweet)
Cancer presenting as Inflammatory low back pain? 34 Cases presenting as SpA over 10 yrs often w/ higher ESR/CRP/LDH levels. CA included myeloma, leukemia, lymphoma, CA of breast/lung/prostate & bone tumors. https://t.co/YYKYx39tbD https://t.co/m9uCbJBsnU
Dr. John Cush @RheumNow ( View Tweet)
Voclosporin and Steroids in Lupus Nephritis
Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.
https://t.co/4CilABzEjm https://t.co/hgyDqG1fPR
Dr. John Cush @RheumNow ( View Tweet)
So You've Got RA and Want to Get Pregnant?
Dr. David Liew reviews abstract POS0436 presented at Eular 2024 in Vienna, Austria.
https://t.co/vG9l7kOReq https://t.co/xhumOCisOM
Dr. John Cush @RheumNow ( View Tweet)
FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis
A controlled trial has shown that apremilast is effective in patients with early, oligoarticular psoriatic arthritis (PsA).
Congrats to 2024 recipients of the Lupus Research Alliance Diversity in Lupus Research Awards:
- Carlos Castrillon PhD, Emory
- Paul Hoover MD, PhD, Brigham
- Renita Horton PhD, U Houston
- Rodrigo Cervantes-Díaz PhD, Boston Childrens
- Jonathan Lagos Orellana MD PhD, Seattle… https://t.co/gtvT4kt7Lt https://t.co/MOdxH2cPM1
Dr. John Cush @RheumNow ( View Tweet)
2612 BSRBR-RA Registry pts on tocilizumab - increasing Body weight was associated with reduced DAS28 response to SC tocilizumab. But the DAS28 difference was small, and did not change drug persistence https://t.co/eR7kmjRaEE https://t.co/vFKYC1I3pV
Dr. John Cush @RheumNow ( View Tweet)
Chinese study of 62 Systemic JIA pts Rx w/ IV Tocilizumab (34 12 mg/kg; 28 8 mg/kg). Wk12 87% responded (JIA ACR 30w/ no fever); Week 52 results were similar. No deaths or macrophage activation syndrome occurred. https://t.co/qGgMCt597x https://t.co/lFDxAgDHfW
Dr. John Cush @RheumNow ( View Tweet)
Swedish population/registry study of incidence of Psoriatic arthritis was estimated at 21.8/100 000 person-years (15.78-28.83/100 000 PY); slightly higher in females, lower w/ higher education, peaks 50-59y. 71% were on DMARD w/in 2 yrs (22% b/ts DMARDs) https://t.co/YTNBHczZ7X https://t.co/KNscF08fKG
Dr. John Cush @RheumNow ( View Tweet)
Retrospective Taiwan's Health claims: studied 6408 RA pts, half HCQ users vs non-users. No higher risk of osteoporosis in HCQ users vs non-users (aHR=0.99; 95% CI: 0.82–1.196). Why study this? HCQ may suppress both bone formation/resorption https://t.co/xShLXMElnH https://t.co/lkvihaYuAd
Dr. John Cush @RheumNow ( View Tweet)
Different Autoantibody Phenotypes in Juvenile and Adult Myositis
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.… https://t.co/fHL14rXAQ6 https://t.co/ZagRU62joJ
Dr. John Cush @RheumNow ( View Tweet)
Systemic Sclerosis Insights (9.13.2024)
https://t.co/fRbKdSAqxG https://t.co/PMbYDXPHMd
Dr. John Cush @RheumNow ( View Tweet)
Congratulations to UCF Associate Professor Justine Tigno-Aranjuez for receiving prestigious U.S. National Science Foundation CAREER Award on her research into NOD2 receptor signaling of lipid mediators contributing to inflammation https://t.co/AkUZbdTSqF https://t.co/usTe2bzyXE
Dr. John Cush @RheumNow ( View Tweet)
24 wk RCT of 683 chronic neck pain pts -acupuncture was more effective in reducing neck pain than sham or waiting (observation), but the magnitude of benefit was below the minimal clinically important change. https://t.co/sqNV8XFYRl https://t.co/hI5Y3z6JiK
Dr. John Cush @RheumNow ( View Tweet)
Metanalysis of JAKi in ILD (7 studies, 183 pts) showed increases in FVC (2 %), DLCO (3.1%) & improved Thoracic HRCT of 11%; only 5% had worsening of their ILD. Risk of ILD w/ JAKi was low ( 0.20/1000 PY) w rates similar to abatacept & rituximab https://t.co/EDaVC6RyZs https://t.co/DMnuBpcJYb
Links:
Dr. John Cush @RheumNow ( View Tweet)
“Big doors swing on little hinges.”
- W. Clement Stone https://t.co/wLfKpwUxzc
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
Systemic Sclerosis Insights (9.13.2024)-
Linger On The Fingers (9.6.2024)
Earlier treatment with biologics to reduce the risk of organ damage-
Running With Data (8.30.2024)
Therapeutic Updates
Earlier treatment with biologics to reduce the risk of organ damage in systemic lupus erythematosus (SLE)
Sponsored by GSK US Medical Affairs
Learn about the importance of reducing organ damage and corticosteroid-associated toxicity in SLE, and how biologics may help to change the course of
the disease by targeting its underlying mechanisms.
Read Post
Are your patients with moderate to severe RA getting the appropriate dose?
Sponsored by Genentech, Inc
Hear experts’ roundtable discussion with Dr. Alvin Wells, Dr. Orrin Troum, Dr. Grace Wright, and Dr. Aaron Broadwell in this video sponsored by Genentech.
Read Post
Poster Hall
